眼血管疾病的基于外体的工程疗法的最新进展
Jian Guan1, Fanhe Meng2, Chuanzhuo Wang2
1Ophthalmology Department, The First Hospital of China Medical University, Liaoning, 110001, China.
Journal of nanobiotechnology
|July 19, 2025
概括
外体体对治疗眼神血管疾病 (OND) 显示出希望,例如AMD和DR,通过克服当前抗VEGF疗法的局限性. 需要对大规模生产和临床使用的安全性进行进一步的研究.
科学领域:
- 眼科医生 眼科 眼科
- 再生医学是一种再生医学.
- 纳米技术纳米技术
背景情况:
- 眼神血管疾病 (OND),包括角膜新血管化 (CoNV),与年龄相关的黄斑变性 (AMD) 和糖尿病视网膜病变 (DR),是导致全球视力损伤的主要原因.
- 目前的治疗方法,如抗血管内皮生长因子 (anti-VEGF) 注射,具有局限性,包括药物耐药性和频繁的服用.
研究的目的:
- 审查使用外体细胞作为OND药物递送平台的进展.
- 探索外生体调节眼球血管生成,炎症和修复的机制.
- 解决基于外体细胞的疗法的临床转化所面临的挑战和未来的前景.
主要方法:
- 批判性审查最近的科学文献在眼部新血管疾病中对外体应用.
- 对外体属性的分析,包括生物相容性,低免疫性和向能力.
- 检查血管生成,炎症和组织修复中的机械作用.
主要成果:
- 外体作为生物活性分子的有效天然载体,比传统疗法具有优势.
- 外体体显示出在OND中调节关键病理过程的潜力.
- 仍然存在重大挑战,包括可扩展的生产,监管批准和安全验证.
结论:
- 外体代表了对OND的有前途的创新治疗策略,可能会彻底改变治疗.
- 克服生产和监管障碍对于临床翻译至关重要.
- 未来的研究应该专注于基于外体细胞的综合和个性化疗法.
相关概念视频
Overview of Exosomes
2.8K
Exosomes are stable, lipid bilayer-enclosed vesicles capable of crossing biological barriers. They can carry a wide range of molecules required for intercellular communication. Once exosomes are released from the cell where they originated, they enter a recipient cell through various pathways such as fusion, receptor-mediated endocytosis, macropinocytosis, and phagocytosis.
Stahl et al. discovered exosomes in 1983, but the exosomes were initially considered waste products released from the...
Stahl et al. discovered exosomes in 1983, but the exosomes were initially considered waste products released from the...
2.8K
Angle Closure Glaucoma: Treatment
691
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
691


